zepbound and tirzepatide the same Zepbound: newest obesity medication explained by an expert Tirzepatide vs. Semaglutide for Weight

71% stop taking GLP-1s by 12 months 6 74% report gastrointestinal symptoms 7 65% report NO increased exercise after starting medication 8 This is why the Noom GLP-1 Rx Program with Noom GLP-1 Companion exists

Not yet as a standalone product

Seek immediate emergency care if you experience severe localized abdominal pain, fever, or signs of peritonitis

With appetite naturally suppressed, building new patterns feels less effortful than it would through willpower alone

This strategy could help employers curb pharmacy costs while boosting worker satisfaction and retention, given the strong demand for GLP-1s among US consumers